Sacubitril And Valsartan Tablet
Product Images NDC 13668-747

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 13668-747). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image (Chemical Structure)

Image (Chemical Structure)
Chemical structure of sacubitril and valsartan, depicting the molecular arrangement of atoms and bonds, including aromatic rings, carboxylate groups, and sodium ions as part of the structure.*
FDA Label Image

24 mg/26 mg (Container Label 24 26)

24 mg/26 mg (Container Label 24 26)
Label for sacubitril and valsartan tablets containing 24 mg of sacubitril and 26 mg of valsartan in each film-coated tablet. The label indicates a supply of 500 tablets, manufactured by Torrent Pharmaceuticals Limited, with dosage form oral tablets. The label also includes storage instructions and a barcode, specifying the product is prescription-only.*
FDA Label Image

49 mg/51 mg (Container Label 49 51)

49 mg/51 mg (Container Label 49 51)
Label for Sacubitril and Valsartan Tablets 49 mg/51 mg, oral film-coated tablets in a container of 500. The label includes storage instructions, caution to keep out of reach of children, manufacturer's details as Torrent Pharmaceuticals Ltd., India, and indicates prescription use only. The label also shows the NDC code 13668-635-05 and a barcode.*
FDA Label Image

97 mg/103 mg (Container Label 97 103)

97 mg/103 mg (Container Label 97 103)
Label for sacubitril and valsartan tablets containing 97 mg sacubitril and 103 mg valsartan per film-coated tablet. The label indicates a bottle size of 500 tablets and includes storage instructions and warnings. Manufactured by Torrent Pharmaceuticals Limited, the label also features the NDC 13668-636-05 and the Torrent Pharma logo. Indicated as Rx only.*
FDA Label Image

Image Description (Figure 01)

Image Description (Figure 01)
A horizontal dot graph showing the geometric mean ratio and 90% confidence interval for sacubitril and valsartan coadministered with various drugs. The graph compares changes in AUC (black dots) and Cmax (white circles) relative to reference values for drugs including furosemide, warfarin, digoxin, carvedilol, levonorgestrel, ethinyl estradiol, amlodipine, HCTZ, metformin, atorvastatin, and sildenafil.*
FDA Label Image

Image Description (Figure 02)

Image Description (Figure 02)
A forest plot showing the geometric mean ratio and 90% confidence interval for AUC and Cmax of LBQ657 and Valsartan across various population descriptions. Categories include renal impairment (mild, moderate, severe), hepatic impairment (mild, moderate), age groups, gender, and ethnicity comparisons with reference values for each.*
FDA Label Image

Image Description (Figure 03 A)

Image Description (Figure 03 A)
A Kaplan-Meier curve showing the time to first occurrence of cardiovascular death or heart failure hospitalizations in the PARADIGM-HF study. The graph compares patients treated with sacubitril and valsartan versus enalapril, with time since randomization (days) on the x-axis and cumulative failure rate (%) on the y-axis. Risk numbers for both groups are listed below the graph.*
FDA Label Image

Image Description (Figure 03 B)

Image Description (Figure 03 B)
A Kaplan-Meier curve depicting time to occurrence of cardiovascular death in the PARADIGM-HF study for sacubitril and valsartan versus enalapril. The x-axis shows time since randomization (days), and the y-axis shows cumulative failure rate percentage. The graph indicates a lower cumulative failure rate over time for sacubitril and valsartan compared to enalapril, with hazard ratio and confidence interval noted.*
FDA Label Image

Image Description (Figure 03 C)

Image Description (Figure 03 C)
A Kaplan-Meier curve chart titled 'Time to First Occurrence of Heart Failure Hospitalizations in PARADIGM-HF' comparing the cumulative failure rate (%) over time (days) since randomization between sacubitril and valsartan and enalapril treatments. The chart includes hazard ratio (HR) with confidence interval and number at risk data for both treatments at various time points up to approximately 1260 days.*
FDA Label Image

Image Description (Figure 04)

Image Description (Figure 04)
A forest plot comparing the hazard ratios (with 95% Confidence Intervals) of sacubitril and valsartan tablets versus enalapril across various patient subgroups. The chart includes subgroup categories such as age, gender, weight, race, region, NYHA class, estimated GFR, diabetes status, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension, prior medication use, hospitalization for heart failure, time since diagnosis, cause of heart failure, and presence of ICD. The plot visually indicates relative efficacy across these subgroups.*
FDA Label Image

Image Description (Figure 5)

Image Description (Figure 5)
A line graph displaying the mean number of events per 100 patients over time since randomization in days, comparing total heart failure hospitalizations and cardiovascular death between sacubitril and valsartan and valsartan alone in the PARAGON-HF study. The graph includes a risk table showing patient numbers at various time points for both treatment groups.*
FDA Label Image

Image Description (Figure 6)

Image Description (Figure 6)
A forest plot chart comparing sacubitril and valsartan tablets with valsartan across various subgroups. The chart shows rate ratios with 95% confidence intervals for overall and specific subgroups including age, gender, race, region, diabetic status, cardiac measures, biomarker levels, and baseline health conditions. It visually represents the comparative effectiveness, with data points and confidence intervals showing whether sacubitril and valsartan or valsartan alone is better for each subgroup.*
FDA Label Image

Image Description (Figure 7)

Image Description (Figure 7)
A dual-panel hazard ratio chart comparing sacubitril and valsartan with enalapril and valsartan across left ventricular ejection fraction percentages at screening. The left panel shows hazard ratios for sacubitril and valsartan vs. enalapril in the PARADIGM-HF study. The right panel compares sacubitril and valsartan vs. valsartan in the PARAGON-HF study. Dashed lines represent 95% confidence intervals, and solid lines show hazard ratios across ejection fraction values.*
FDA Label Image
Image Description (Torrent Logo)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.